PURA and hepatocellular carcinoma: In HepG2 cells, miR-23a and miR-27a induced cell cycle progression by directly targeting PURA, implicating cancer cell proliferation by inhibiting cell cycle progression at G1-S or G2-M checkpoints [39], resulting in increased HCC cell growth.